\-\ Texto\\:\\ \ \(0\)\
\-\ slender\\ male\\,\\ currently\\ asymptomatic\\.\ \(0\)\
\-\ thus\\ far\\,\\ this\\ patient\\ has\\ been\\ received\\ medical\\ therapy\\ only\\.\\ \\ interval\\ clinical\\ and\\ radiologic\\ reevaluation\\ is\\ planned\\,\\ with\\ the\\ reevaluation\\ interval\\ to\\ be\\ determined\\ based\\ on\\ symptoms\\ and\\ disease\\ progression\\.\ \(0\)\
\-\ several\\ regions\\ of\\ discontinuous\\ and\\ asymmetric\\ bowel\\ wall\\ thickening\\ with\\ alternating\\ regions\\ of\\ dilation\\.\\ \\ no\\ fistulas\\ were\\ identified\\ in\\ this\\ patient\\‚\\Ä\\ôs\\ case\\.\\ \\ enhancement\\ localized\\ to\\ the\\ regions\\ of\\ mural\\ thickening\\ was\\ demonstrated\\ following\\ the\\ administration\\ of\\ intravenous\\ gadolinium\\ dtpa\\.\ \(0\)\
\-\ crohn\\ disease\ \(0\)\
\-\ \\&\\#61550\\;\\	ulcerative\\ colitis\\ \\(\\‚\\Ä\\úbackwash\\ ileitis\\‚\\Ä\\ù\\)\ \(0\)\
\-\ \\&\\#61550\\;\\	infection\ \(0\)\
\-\ \\&\\#61550\\;\\	ischemia\ \(0\)\
\-\ \\&\\#61550\\;\\	radiation\\ enteritis\ \(0\)\
\-\ \\&\\#61550\\;\\	metastases\\ \\/\\ lymphoma\ \(0\)\
\-\ 54\\ year\\-old\\ male\\ with\\ recurrent\\ abdominal\\ pain\\ and\\ diarrhea\\.\ \(1\)\
\-\ the\\ exact\\ etiology\\ of\\ crohn\\‚\\Ä\\ôs\\ disease\\ is\\ unknown\\.\\ \\ there\\ is\\ a\\ familial\\ disposition\\.\\ \\ most\\ common\\ age\\ of\\ presentation\\ is\\ 15\\-25\\ years\\,\\ with\\ an\\ equal\\ distribution\\ between\\ the\\ sexes\\.\\ \\ there\\ is\\ a\\ four\\-fold\\ increase\\ in\\ incidence\\ amongst\\ smokers\\.\\ \\ the\\ most\\ common\\ presenting\\ symptoms\\ include\\ diarrhea\\,\\ pain\\,\\ melena\\,\\ weight\\ loss\\ and\\ fever\\.\\ \\ \ \(0\)\
\-\ associated\\ abnormalities\\ include\\ arthritis\\,\\ cholelithiasis\\,\\ sclerosing\\ cholangitis\\,\\ uveitis\\ and\\ ankylosing\\ spondylitis\\.\\ \\ based\\ on\\ pathology\\,\\ there\\ are\\ three\\ stages\\ of\\ crohn\\‚\\Ä\\ôs\\ disease\\.\\ \\ the\\ early\\ stage\\ includes\\ hyperplasia\\ of\\ lymphoid\\ tissue\\ and\\ shallow\\ mucosal\\ erosions\\ \\(aphthoid\\ ulcers\\)\\.\\ \\ the\\ intermediate\\ stage\\ is\\ defined\\ by\\ transmural\\ extension\\ within\\ the\\ mucosa\\ and\\ subserosa\\ with\\ marked\\ fold\\ thickening\\.\\ \\ the\\ advanced\\ stage\\ includes\\ transmural\\ extension\\ to\\ and\\ through\\ the\\ serosa\\ and\\ deep\\ ulcerations\\ and\\ fissures\\.\ \(0\)\
\-\ lesions\\ can\\ occur\\ anywhere\\ along\\ the\\ entire\\ length\\ of\\ the\\ gut\\,\\ from\\ the\\ mouth\\ to\\ the\\ anus\\.\\ \\ the\\ terminal\\ ileum\\ and\\ proximal\\ colon\\ are\\ the\\ most\\ common\\ sites\\ of\\ involvement\\.\\ \\ skip\\ lesions\\ more\\ commonly\\ involve\\ the\\ distal\\ ileum\\.\ \(0\)\
\-\ 10\\-20\\%\\ of\\ patients\\ lead\\ symptom\\-free\\ lives\\.\\ \\ medical\\ treatment\\ includes\\ steroids\\,\\ azathioprine\\,\\ mesalamine\\,\\ and\\ antibiotics\\.\\ \\ surgical\\ treatment\\ involves\\ resection\\ of\\ the\\ affected\\ bowel\\.\\ \\ 30\\-53\\%\\ recur\\ after\\ surgical\\ resection\\.\ \(0\)\
\-\ references\\:\ \(0\)\
\-\ gore\\ rm\\,\\ et\\ al\\.\\ \\ ct\\ features\\ of\\ ulcerative\\ colitis\\ and\\ crohn\\‚\\Ä\\ôs\\ disease\\.\\ \\ am\\ j\\ roentgenl\\.\\ \\ 167\\(1\\)\\:3\\-15\\,\\ 1996\\.\ \(0\)\
\-\ hizawa\\ k\\,\\ et\\ al\\.\\ \\ crohn\\ disease\\:\\ early\\ recognition\\ and\\ progress\\ of\\ aphthous\\ lesions\\.\\ \\ radiology\\.\\ \\ 190\\(2\\)\\:451\\-4\\,\\ 1994\\.\ \(0\)\
\-\ Keywords\\ by\\ value\\:\\ \ \(0\)\
\-\ 61550\\:\\ 0\\.41207669206806896\ \(0\)\
\-\ crohn\\:\\ 0\\.2508360169986523\ \(0\)\
\-\ the\\:\\ 0\\.1953780774756767\ \(0\)\
\-\ and\\:\\ 0\\.15973548194033652\ \(0\)\
\-\ reevaluation\\:\\ 0\\.15230651427495645\ \(0\)\
\-\ transmural\\:\\ 0\\.15230651427495645\ \(0\)\
\-\ of\\:\\ 0\\.14119180713735147\ \(0\)\
\-\ regions\\:\\ 0\\.13268689765689815\ \(0\)\
\-\ disease\\:\\ 0\\.12979482865217037\ \(0\)\
\-\ stage\\:\\ 0\\.12311909691191825\ \(0\)\
\-\ includes\\:\\ 0\\.12022186512987558\ \(0\)\
\-\ fold\\:\\ 0\\.11919442958938961\ \(0\)\
\-\ ulcerative\\:\\ 0\\.11590014393388712\ \(0\)\
\-\ thickening\\:\\ 0\\.10517988516990295\ \(0\)\
\-\ ileum\\:\\ 0\\.10430277669258044\ \(0\)\
\-\ colitis\\:\\ 0\\.10192972593956474\ \(0\)\
\-\ diarrhea\\:\\ 0\\.0975128092641717\ \(0\)\
\-\ interval\\:\\ 0\\.09326453710039036\ \(0\)\
\-\ lesions\\:\\ 0\\.08879103275449603\ \(0\)\
\-\ common\\:\\ 0\\.08767837572816237\ \(0\)\
\-\ is\\:\\ 0\\.08467890398917194\ \(0\)\
\-\ aphthoid\\:\\ 0\\.08241533841361379\ \(0\)\
\-\ subserosa\\:\\ 0\\.08241533841361379\ \(0\)\
\-\ roentgenl\\:\\ 0\\.08241533841361379\ \(0\)\
\-\ hizawa\\:\\ 0\\.08241533841361379\ \(0\)\
\-\ al\\:\\ 0\\.08189502341079313\ \(0\)\
\-\ et\\:\\ 0\\.08074037454811923\ \(0\)\
\-\ most\\:\\ 0\\.08046078607331444\ \(0\)\
\-\ slender\\:\\ 0\\.0787522556906064\ \(0\)\
\-\ backwash\\:\\ 0\\.07615325713747823\ \(0\)\
\-\ mesalamine\\:\\ 0\\.07615325713747823\ \(0\)\
\-\ gore\\:\\ 0\\.07615325713747823\ \(0\)\
\-\ aphthous\\:\\ 0\\.07615325713747823\ \(0\)\
\-\ based\\:\\ 0\\.0746608100574059\ \(0\)\
\-\ early\\:\\ 0\\.07429577648656142\ \(0\)\
\-\ sexes\\:\\ 0\\.07413731724222208\ \(0\)\
\-\ serosa\\:\\ 0\\.07413731724222208\ \(0\)\
\-\ extension\\:\\ 0\\.07296105564067908\ \(0\)\
\-\ disposition\\:\\ 0\\.07249017441447084\ \(0\)\
\-\ amongst\\:\\ 0\\.07249017441447084\ \(0\)\
\-\ uveitis\\:\\ 0\\.07109753499686541\ \(0\)\
\-\ discontinuous\\:\\ 0\\.06989117586134266\ \(0\)\
\-\ skip\\:\\ 0\\.06989117586134266\ \(0\)\
\-\ azathioprine\\:\\ 0\\.06989117586134266\ \(0\)\
\-\ ileitis\\:\\ 0\\.06787523596608652\ \(0\)\
\-\ rm\\:\\ 0\\.06787523596608652\ \(0\)\
\-\ 167\\:\\ 0\\.06787523596608652\ \(0\)\
\-\ smokers\\:\\ 0\\.0670141777246094\ \(0\)\
\-\ ulcerations\\:\\ 0\\.0670141777246094\ \(0\)\
\-\ bowel\\:\\ 0\\.06614549536492428\ \(0\)\
\-\ resection\\:\\ 0\\.06606893360967005\ \(0\)\
\-\ 190\\:\\ 0\\.06550496541730966\ \(0\)\
\-\ medical\\:\\ 0\\.06550483325222402\ \(0\)\
\-\ gut\\:\\ 0\\.06483545372072985\ \(0\)\
\-\ lymphoid\\:\\ 0\\.06308139516465573\ \(0\)\
\-\ recognition\\:\\ 0\\.06308139516465573\ \(0\)\
\-\ alternating\\:\\ 0\\.06256501041532787\ \(0\)\
\-\ melena\\:\\ 0\\.06256501041532787\ \(0\)\
\-\ fistulas\\:\\ 0\\.06161315468995095\ \(0\)\
\-\ enteritis\\:\\ 0\\.06161315468995095\ \(0\)\
\-\ there\\:\\ 0\\.06151659158387991\ \(0\)\
\-\ include\\:\\ 0\\.0613254542980753\ \(0\)\
\-\ dtpa\\:\\ 0\\.06075209644847382\ \(0\)\
\-\ fissures\\:\\ 0\\.06075209644847382\ \(0\)\
\-\ lives\\:\\ 0\\.06075209644847382\ \(0\)\
\-\ recur\\:\\ 0\\.06075209644847382\ \(0\)\
\-\ anus\\:\\ 0\\.06035050706328557\ \(0\)\
\-\ shallow\\:\\ 0\\.0599660118621997\ \(0\)\
\-\ anywhere\\:\\ 0\\.0599660118621997\ \(0\)\
\-\ cholangitis\\:\\ 0\\.059597214794694806\ \(0\)\
\-\ 1994\\:\\ 0\\.058573372444594284\ \(0\)\
\-\ exact\\:\\ 0\\.056557432549338135\ \(0\)\
\-\ symptoms\\:\\ 0\\.056393828805303636\ \(0\)\
\-\ familial\\:\\ 0\\.056055399309942903\ \(0\)\
\-\ ankylosing\\:\\ 0\\.055579801418166694\ \(0\)\
\-\ stages\\:\\ 0\\.05512799359570789\ \(0\)\
\-\ spondylitis\\:\\ 0\\.05491028972158689\ \(0\)\
\-\ sclerosing\\:\\ 0\\.054286989243936164\ \(0\)\
\-\ ulcers\\:\\ 0\\.054286989243936164\ \(0\)\
\-\ terminal\\:\\ 0\\.05298080286503852\ \(0\)\
\-\ planned\\:\\ 0\\.05280871626003523\ \(0\)\
\-\ mural\\:\\ 0\\.052639846416184924\ \(0\)\
\-\ intermediate\\:\\ 0\\.052639846416184924\ \(0\)\
\-\ far\\:\\ 0\\.05247407527708211\ \(0\)\
\-\ progress\\:\\ 0\\.05247407527708211\ \(0\)\
\-\ cholelithiasis\\:\\ 0\\.05168799069080799\ \(0\)\
\-\ erosions\\:\\ 0\\.05168799069080799\ \(0\)\
\-\ to\\:\\ 0\\.05153437885719912\ \(0\)\
\-\ mouth\\:\\ 0\\.05082693244933086\ \(0\)\
\-\ with\\:\\ 0\\.050455774717311386\ \(0\)\
\-\ sites\\:\\ 0\\.050295351273202574\ \(0\)\
\-\ surgical\\:\\ 0\\.05009517196193841\ \(0\)\
\-\ mucosa\\:\\ 0\\.04967205079555184\ \(0\)\
\-\ equal\\:\\ 0\\.04931772014203113\ \(0\)\
\-\ treatment\\:\\ 0\\.04909750407161313\ \(0\)\
\-\ determined\\:\\ 0\\.04908899213767982\ \(0\)\
\-\ am\\:\\ 0\\.04864820844545133\ \(0\)\
\-\ 54\\:\\ 0\\.04854129271712845\ \(0\)\
\-\ mucosal\\:\\ 0\\.04854129271712845\ \(0\)\
\-\ advanced\\:\\ 0\\.04843562749383944\ \(0\)\
\-\ radiologic\\:\\ 0\\.04802490796780061\ \(0\)\
\-\ thus\\:\\ 0\\.047348229056562684\ \(0\)\
\-\ progression\\:\\ 0\\.0472555690278459\ \(0\)\
\-\ intravenous\\:\\ 0\\.046983158231058524\ \(0\)\
\-\ hyperplasia\\:\\ 0\\.046983158231058524\ \(0\)\
\-\ length\\:\\ 0\\.046983158231058524\ \(0\)\
\-\ entire\\:\\ 0\\.0468941498893772\ \(0\)\
\-\ asymmetric\\:\\ 0\\.04637776514004936\ \(0\)\
\-\ localized\\:\\ 0\\.046294499356129525\ \(0\)\
\-\ male\\:\\ 0\\.04589053638406963\ \(0\)\
\-\ lead\\:\\ 0\\.04588930707015465\ \(0\)\
\-\ dilation\\:\\ 0\\.04535093575946941\ \(0\)\
\-\ involve\\:\\ 0\\.04535093575946941\ \(0\)\
\-\ steroids\\:\\ 0\\.045276579178383146\ \(0\)\
\-\ received\\:\\ 0\\.044842850756800404\ \(0\)\
\-\ involves\\:\\ 0\\.044842850756800404\ \(0\)\
\-\ ischemia\\:\\ 0\\.04463355320468047\ \(0\)\
\-\ incidence\\:\\ 0\\.044361825244793214\ \(0\)\
\-\ distribution\\:\\ 0\\.043716245412811286\ \(0\)\
\-\ gadolinium\\:\\ 0\\.042940551021590105\ \(0\)\
\-\ affected\\:\\ 0\\.04238612716931576\ \(0\)\
\-\ arthritis\\:\\ 0\\.04191466679700858\ \(0\)\
\-\ metastases\\:\\ 0\\.04166299944829014\ \(0\)\
\-\ etiology\\:\\ 0\\.041515296862415625\ \(0\)\
\-\ features\\:\\ 0\\.04146659446089728\ \(0\)\
\-\ increase\\:\\ 0\\.04136997029275634\ \(0\)\
\-\ recurrent\\:\\ 0\\.04132204299943655\ \(0\)\
\-\ radiology\\:\\ 0\\.04127436862177033\ \(0\)\
\-\ references\\:\\ 0\\.041086147780427115\ \(0\)\
\-\ administration\\:\\ 0\\.041039698970639416\ \(0\)\
\-\ pathology\\:\\ 0\\.040456640312767383\ \(0\)\
\-\ presenting\\:\\ 0\\.04037018727405962\ \(0\)\
\-\ deep\\:\\ 0\\.040115683863913794\ \(0\)\
\-\ currently\\:\\ 0\\.039587688428496484\ \(0\)\
\-\ colon\\:\\ 0\\.039239429195636215\ \(0\)\
\-\ are\\:\\ 0\\.03911021331025257\ \(0\)\
\-\ unknown\\:\\ 0\\.039051599694034586\ \(0\)\
\-\ marked\\:\\ 0\\.038977547856454194\ \(0\)\
\-\ commonly\\:\\ 0\\.038133266358150585\ \(0\)\
\-\ antibiotics\\:\\ 0\\.03796688460949715\ \(0\)\
\-\ occur\\:\\ 0\\.037901180511871475\ \(0\)\
\-\ abnormalities\\:\\ 0\\.03733040502870295\ \(0\)\
\-\ involvement\\:\\ 0\\.037299728348624266\ \(0\)\
\-\ pain\\:\\ 0\\.03688208436587209\ \(0\)\
\-\ defined\\:\\ 0\\.03676464788956165\ \(0\)\
\-\ identified\\:\\ 0\\.03653664150137771\ \(0\)\
\-\ weight\\:\\ 0\\.03593776561109752\ \(0\)\
\-\ presentation\\:\\ 0\\.03547568500111698\ \(0\)\
\-\ this\\:\\ 0\\.035416559542067266\ \(0\)\
\-\ asymptomatic\\:\\ 0\\.03508389358789886\ \(0\)\
\-\ fever\\:\\ 0\\.034941244198913465\ \(0\)\
\-\ three\\:\\ 0\\.03459417436443154\ \(0\)\
\-\ along\\:\\ 0\\.03452633219128528\ \(0\)\
\-\ radiation\\:\\ 0\\.034151229104157625\ \(0\)\
\-\ several\\:\\ 0\\.03381187376715629\ \(0\)\
\-\ patient\\:\\ 0\\.03352335611557319\ \(0\)\
\-\ between\\:\\ 0\\.033484805520273324\ \(0\)\
\-\ clinical\\:\\ 0\\.032660323335244934\ \(0\)\
\-\ age\\:\\ 0\\.03235404744184992\ \(0\)\
\-\ only\\:\\ 0\\.03219600947129352\ \(0\)\
\-\ proximal\\:\\ 0\\.03219600947129352\ \(0\)\
\-\ demonstrated\\:\\ 0\\.03167189155341926\ \(0\)\
\-\ years\\:\\ 0\\.03159013286327267\ \(0\)\
\-\ loss\\:\\ 0\\.03139687900029359\ \(0\)\
\-\ wall\\:\\ 0\\.03134920462262737\ \(0\)\
\-\ infection\\:\\ 0\\.031129991388616017\ \(0\)\
\-\ on\\:\\ 0\\.031128778561756394\ \(0\)\
\-\ following\\:\\ 0\\.030915971514710292\ \(0\)\
\-\ lymphoma\\:\\ 0\\.030692154776368878\ \(0\)\
\-\ through\\:\\ 0\\.030677428980765017\ \(0\)\
\-\ been\\:\\ 0\\.03002474872566802\ \(0\)\
\-\ distal\\:\\ 0\\.02994299003552143\ \(0\)\
\-\ enhancement\\:\\ 0\\.029662524429353528\ \(0\)\
\-\ therapy\\:\\ 0\\.029610075668963856\ \(0\)\
\-\ patients\\:\\ 0\\.028991134310144495\ \(0\)\
\-\ more\\:\\ 0\\.02829810831993384\ \(0\)\
\-\ abdominal\\:\\ 0\\.028185740284217116\ \(0\)\
\-\ associated\\:\\ 0\\.027162695627252317\ \(0\)\
\-\ can\\:\\ 0\\.027043821891091294\ \(0\)\
\-\ tissue\\:\\ 0\\.027033985990715558\ \(0\)\
\-\ were\\:\\ 0\\.02656469193106271\ \(0\)\
\-\ case\\:\\ 0\\.025890514975612015\ \(0\)\
\-\ in\\:\\ 0\\.025640363375597677\ \(0\)\
\-\ after\\:\\ 0\\.025000368415631732\ \(0\)\
\-\ within\\:\\ 0\\.02373533225892697\ \(0\)\
\-\ has\\:\\ 0\\.023539587631424958\ \(0\)\
\-\ by\\:\\ 0\\.02188465807472782\ \(0\)\
\-\ be\\:\\ 0\\.020905601529605373\ \(0\)\
\-\ from\\:\\ 0\\.020467431268109498\ \(0\)\
\-\ an\\:\\ 0\\.019706728327616364\ \(0\)\
\-\ ct\\:\\ 0\\.019619776033645953\ \(0\)\
\-\ was\\:\\ 0\\.01796038236436949\ \(0\)\
\-\ no\\:\\ 0\\.016758525283857295\ \(0\)\
